Clinical Trials

Accrual Status
Limit to SWOG Trials

1033 Results

Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0353
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0408

A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab for Resectable Colorectal Metastases in the Liver

Research Committee(s)
Gastrointestinal Cancer
Activated
11-15-2006
Closed
04-01-2007
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0530
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0528

Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
09-01-2006
Closed
08-25-2009
ClinicalTrials.gov Registry Number
NCT00352443
Closed
Phase
Accrual
99%
Published
SWOG Clinical Trial Number
S0421
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
0%
SWOG Clinical Trial Number
S0506
Closed
Phase
Accrual
100%
Published
Closed
Phase
Accrual
25%
Published
SWOG Clinical Trial Number
S0526

Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Research Committee(s)
Lung Cancer
Activated
07-01-2006
Closed
10-01-2008
Closed
Phase
Accrual
91%
Published
Closed
Phase
Accrual
9%
SWOG Clinical Trial Number
S0425
Closed
Phase
Accrual
95%
Published
SWOG Clinical Trial Number
S0618
Closed
Phase
Accrual
40%
Published
SWOG Clinical Trial Number
S0429
Closed
Phase
Accrual
58%
Published
SWOG Clinical Trial Number
S0434
Closed
Phase
Accrual
56%
Published
SWOG Clinical Trial Number
S0512

Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma

Research Committee(s)
Melanoma
Activated
03-15-2006
Closed
01-01-2009
ClinicalTrials.gov Registry Number
NCT00329641
Closed
Phase
Accrual
68%
Published
SWOG Clinical Trial Number
S0505
Closed
Phase
Accrual
55%
Published
SWOG Clinical Trial Number
S0520

Phase II Study of PXD101 (NSC-726630) in Relapsed and Refractory Aggressive B-Cell Lymphomas

Research Committee(s)
Lymphoma
Activated
01-01-2006
Closed
05-01-2009